Table 1.
Clinical characteristics (n=30)
| PCNSL (n = 18) | SCNSL (n = 12) | |
|---|---|---|
| Age at ASCT, median years (range) | 54 (24,69) | 63 (53,74) |
| Gender, male / female | 7 / 11 | 6 / 6 |
| Histology | ||
| Diffuse Large B-cell Lymphoma (%) | 18 (100) | 9 (75) |
| CLL / SLL (%) | 0 (0) | 2 (17) |
| Follicular NHL (%) | 0 (0) | 1 (8) |
| Prior Treatment History | ||
| High-dose IV MTX (%) | 18 (100) | 11 (92) |
| High-dose Cytarabine (%) | 2 (11) | 1 (8) |
| Rituximab (IV) (%) | 18 (100) | 12 (100) |
| WBRT (%) | 0 (0) | 2 (17) |
| Other XRT (%) | 1 (6) | 7 (58) |
| Response at enrollment | ||
| CR1 / PR1 | 12 (67) | 5 (42) |
| CR2 / PR2 or beyond | 6 (33) | 7 (58) |
| Time from diagnosis to ASCT, median months (range) | 6.8 (4.8, 42.1) | 23.2 (6.7, 130.3) |
| CD34+ cells / kg infused, median (range)* | 18.7 (2.3, 34.9) | 5.9 (2.1, 27.4) |
*
Values expressed are × 106 / kg of recipient actual body weight